49results about How to "No lethal effect" patented technology

The invention relates to applications of nicotinamide adenine dinucleotide in the field of pharmacy, and more specifically relates to applications of nicotinamide adenine dinucleotide in preparation of a medicine used for curing liver damages caused by chemotherapy drug doxorubicin hydrochloride. NAD<+> is capable of preventing and treating liver damages caused by chemotherapy drug doxorubicin hydrochloride effectively; and it is also found that NAD<+> is capable of killing glioma cells, neuronal tumor cells, gastric cancer cells, renal tumor cells or breast tumor cells effectively, but possesses no killing effect on normal primary cells.

The invention discloses a CD47-targted antibody and a production method and application thereof, particularly discloses a novel CD47-targeted mouse antibody or a novel CD47-targeted human-mouse chimeric antibody, and discloses a method for producing the monoclonal antibody. The monoclonal antibody can bind to a CD47 antigen highly specifically, has very high affinity, and has the activity of significant anti-tumor activity and the like.

The invention relates to the field of biological medicines, in particular to a single-chain antibody specifically bound with CLDN18.2 and a chimeric antigen receptor (CAR) containing the single-chain antibody. The invention also relates to reconstructed immune cells expressing the CAR, or co-expressing the CAR and a further bioactive molecule (e.g., a PD-1 antibody or mIL-15), nucleic acid molecules encoding such CAR or co-expressed molecules, and methods of preparing the reconstructed immune cells. The invention also relates to application of the CAR and the immune cells in preventing and / or treating cancers such as gastric cancer, gastric adenocarcinoma and pancreatic cancer and a method for preventing and / or treating the cancers such as the gastric cancer, the gastric adenocarcinoma and the pancreatic cancer.

The invention discloses a preparation method of a protozoa cyst transmission electron microscope sample, which is characterized in that a traditional fixing method is improved, and glutaraldehyde and Tritan X-100 are used for treating a cyst under the condition of not damaging the cyst, the glutaraldehyde plays a fixing role, and Tritan X-100 has the characteristic of increasing the permeability of a eukaryotic cell membrane, has no killing effect on microorganisms, and can promote a stationary liquid to penetrate through a cyst wall, so that a sample is quickly fixed, and the difficulty that the sample is not fully fixed in the past is solved. An Epon812 epoxy resin embedding agent in a traditional method is replaced by the Spurr embedding agent, so that the embedding agent can better and completely permeate into the cyst. According to the method, the treatment conditions in each step are optimized according to the characteristics of the cyst, so that the effectiveness of a sample preparation result is improved, and a basis is provided for clearly presenting the sample. The method can be applied to preparation of most protozoa cyst TEM samples, and has certain stability and repeatability.

The invention relates to a recombinant adeno-associated virus AAV-shCdc6 formulation, which contains the recombinant adeno-associated virus AAV-shCdc6 which is obtained by inserting the small interfering RNA (siRNA) of a specific human Cdc6RNAi targeting sequence to the special site of the AAV (Adeno-Associated Virus). The recombinant adeno-associated virus AAV-shCdc6 formulation provided by the invention is capable of efficiently infecting the breast cancer cells and continuously expressing the siRNA of the specific targeting Cdc6, and finally capable of specifically killing the breast cancer cells; on the contrary, the recombinant adeno-associated virus AAV-shCdc6 formulation has no killing effect on normal mammary epithelial cells. Therefore, the recombinant adeno-associated virus AAV-shCdc6 formulation can be used as a novel biological formulation for treating the breast cancer.

The invention discloses target specific double mutant fusion protein, which is established by human gonadotropin releasing hormone mutant (mGnRH) and recombinant pseudomonas aeruginosa exotoxin A mutant (PE38m4a) fusion protein. The mGnRH-PE38m4a protein provided by the invention has obvious specific binding activity and cytotoxicity to the tumor cell lines which comprise colon cancer HT-29 cells, oophoroma OVCAR3 cells, cervical adenocarcinoma HeLa cells or liver cancer HepG-2 cells, and the like; the normal cells basically have no lethal function; the activity of the fusion protein is enhanced by approximate nine to ten times compared with the activity of natural PEA; the cost is low, the method is simple, therefore the target specific double mutant fusion protein is more suitable for industrialized production.